Coronary Artery Disease, Hyperlipidemia
Conditions
Brief summary
This multicentre, open-label, single-arm Study is to evaluate the effect of Rosuvastatin 20 mg 76 weeks on coronary atherosclerosis plaque versus baseline in Chinese coronary heart disease (CHD) patients with hyperlipidemia by measuring the plaque volume using a 64 slice spiral CT. Effect on blood lipids, hsCRP and Carotid intima-media thickness (CIMT) is also evaluated.
Interventions
DRUGRosuvastatin
Rosuvastatin 20 mg per day for 76 weeks
Sponsors
Peking University First Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Written informed consent * Men or women, aged 18 -75 * Diagnosed with coronary heart disease (CHD) stable angina for more than 1 month and meet the following any one: 1. History of myocardial infarction. 2. CHD confirmed by coronary angiography. 3. Excercise ECG positive for CHD or perfusion defect 4. One or more main branch of coronary artery stenosis ≥ 50% confirmed by CT scanning. * Hyperlipidemia (lipid-lowering treatment naïve: LDL-C ≥130mg/dl, or having received lipid-lowering treatment: LDL-C ≥100mg/dl) * The 64 slice CT shows at least one significant coronary artery stenosis ≥20% with the narrowest ≤60% and meeting the following criteria: 1. Diameter of coronary artery lesion ≥2mm, length ≥5mm; distance between multiple lesions \>1cm 2. Plaque density \<100HU, no calcification 3. Vascular stenosis (20～60%) caused by plaques 4. Plaque thickness \>1mm 5. Plaque not in the coronary artery with previous PCI treatment.
Exclusion criteria
* Acute myocardial infarction within 6 months * PCI or CABG therapy within 6 months * Anticipated PCI or CABG therapy in the following 3 months. * Tropnin I/Tropnin T higher than ULN * Cardiac failure NYHA III or above * Coronary artery left main stenosis \>50% * Emergency coronary angiography(CAG) is needed * Serious arrhythmia or tachycardia * Secondary hyperlipidemia * Familial hypercholestrolemia * Uncontrolled severe hypertension (≥200/110 mmHg) * Uncontrolled diabetes (HbA1c ≥9.5%) * Triglyceride ≥500 mg/dL (5.65 mmol/L) * Active hepatic disease or hepatic function impairment, ALT≥3ULN * Serum creatinine \>177 µmol/L (2.0 mg/dL) * Myalgia or blood CK ≥5ULN * WBC \< 4×10e9/L，or PLT \< 100\*10e9/L。 * Participation in the the course of plan and/or procedure of this study * Previous participation in the study treatment * Participation in other clinical studies in the past 3 months * Pregnant or breast-feeding women, women with child-bearing potential who did not use drugs or devices for contraception, or women with positive urine pregnancy test (human chorionic gonadotropin \[HCG\]) * History of malignant tumors (exception: recovered more than 10 years or only basal cell carcinoma or squamous cell carcinoma); females with a history of cervical atypical hyperplasia (exception: 3 consecutive cervical smear tests normal prior to enrolment) * History of alcohol and/or drug abuse in recent 5 years * Any serious or unstable physical or psychological conditions, in the opinion of the investigator, would compromise the safety of the patient or the participation in this study * Use of concomitant medications prohibited in this study ( Erythromycin, clarithromycin, erythromycin ethylsuccinate, sulfaphenazole; Fluconazole, ketoconazole, itraconazole; Niacin / nicotinic acid(including vitamins/food additives containing niacin / nicotinic acid \>50mg), probucol, clofibrate, cholestyramine, colestipol hydrochloride, ezetimibe, fenofibrate, gemfibrozil, atorvastatin(exception: study medication)，lovastatin, pravastatin, rosuvastatin (exception: study medication) , Simvastatin, fluvastatin, fish oil (any dose), lipid-lowering supplements and food additives; Cyclosporine; Protease inhibitors) * Use of periodic hormone replacement treatment(HRT), oral contraceptives(OCTs), long-acting progesterone, or in recent 3 months non-periodic HRT or OCTs * Patients with any condition which, in the investigator's judgment, might increase the risk to the subject for any adverse event or abnormal laboratory finding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in coronary atherosclerosis plaque volume using a 64 slice spiral CT at 76 weeks | 76 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline in hsCRP at 26 weeks | 26 weeks |
| Change from baseline in Carotid intima-media thickness at 76 weeks | 76 weeks |
| Number of participants with adverse events and abnormal laboratory safety markers. | 76 weeks |
| Change from baseline in blood lipids at 26 weeks | 26 weeks |
| Change from baseline in blood lipids at 76 weeks | 76 weeks |
| Change from baseline in hsCRP at 52 weeks | 52 weeks |
| Change from baseline in hsCRP at 76 weeks | 76 weeks |
| Change from baseline in blood lipids at 52 weeks | 52 weeks |
Countries
China
Contacts
Primary ContactJie Jiang, MD
Outcome results
None listed